Structure and activity of hydrogenated derivatives of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801)
摘要:
Several hydrogenated derivatives of the potent NMDA antagonist 1 have been prepared and evaluated as competitive inhibitors of [3H]-1 binding. These compounds were also tested for their ability to act as noncompetitive antagonists of NMDA in vitro. These studies indicate that two aromatic rings are not strictly required for high-affinity binding or NMDA antagonism.
New Synthetic Route to 10,11-Dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>]cyclohepten-5,10-imines through Photoamination of 5-Alkoxy- and 5-Hydroxy-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>]cycloheptenes Followed by a Transannular Reaction with Acetic Acid
The photoadditions of ammonia and alkylamines (RNH2) to 5-hydroxy- and 5-alkoxy-5H-dibenzo[a,d]cycloheptene derivatives (2) occurred at the C10–C11 double bond upon the irradiation of 2 with RNH2 in the presence of p-dicyanobenzene. The resulting 5-substituted 10-alkylamino-10,11-dihydro-5H-dibenzo[a,d]cycloheptenes were converted to 5-substituted N-alkyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imines by a treatment with AcOH.
NOMOTO, TAKASHI;TAKAYAMA, HIROAKI, HETEROCYCLES, 1984, 22, N 9, 1969-1972
作者:NOMOTO, TAKASHI、TAKAYAMA, HIROAKI
DOI:——
日期:——
TAKAYAMA H.; NOMOTO T.; SUZUKI T.; TAKAMOTO M.; OKAMOTO T., HETEROCYCLES, 1979, 12, NO 1, 179
作者:TAKAYAMA H.、 NOMOTO T.、 SUZUKI T.、 TAKAMOTO M.、 OKAMOTO T.
DOI:——
日期:——
CONJUGATES OF HUPERZINE AND ANALOGS THEREOF
申请人:INSERO HEALTH INC.
公开号:US20150191430A1
公开(公告)日:2015-07-09
Compounds and compositions for treating neurodegenerative diseases are described. The compounds include a therapeutic agent covalently linked with huperzine or an analog thereof through a linker. Methods of preparing the compounds are described. Methods of treating a neurodegenerative disease by administering compounds and compositions including a therapeutic agent covalently linked with huperzine or an analog thereof are described. Methods for delivering a therapeutic agent by administering the therapeutic agent covalently linked to huperzine or an analog thereof are described.